What does collaboration revenue (ZURZUVAE) — total revenues mean?

This metric represents the total revenue recognized from collaborative arrangements or licensing agreements associated with a specific pharmaceutical product or therapeutic candidate. It reflects the financial inflows generated through partnerships, milestone payments, or profit-sharing models rather than direct product sales. Monitoring this revenue stream provides insight into the company's ability to monetize its research and development pipeline through strategic external alliances.

Supernus Pharmaceuticals (SUPN) Collaboration revenue (ZURZUVAE) — Total revenues

Screener

Other product segments

Qelbree

$77.84M+20.2%

GOCOVRI

$35.24M+14.8%

Royalty, licensing, and other revenues

$29.31M+274%

Trokendi XR

$9.48M-26.0%

ONAPGO

$8.38M—

APOKYN

$7.73M-48.4%

Oxtellar XR

$7.42M-27.2%

Other

$4.67M-45.6%

Similar metrics at other companies

QTRXCollaboration and license revenue — Total revenues

$560K-27.4%

NBIXCollaboration revenues — Total revenues

$3.5M-60.7%

EXELCollaboration — Total revenues

$55.67M+15.4%

EXELCollaboration services revenues — Total revenues

-$4.53M-80.8%

RCUSOther collaboration — Total revenues

$25M+213%

VIRLicense and collaboration revenue — Total revenues

$238.94M+48,370%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.72B+14.3%

Enterprise value$2.57B+13.6%

P/S3.5×-0.1×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed: May 5, 2026, 4:15 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001356576-26-000022

Line item	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Revenues
Net product sales	$150,753	$141,988
Collaboration revenue (ZURZUVAE)	27,643	—
Royalty, licensing, and other revenues	29,309	7,836
Total revenues	207,705	149,824
Costs and expenses
Cost of revenues(a)	23,391	15,763
Research and development	39,438	26,927

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's collaboration revenue (ZURZUVAE) — total revenues?: Supernus Pharmaceuticals (SUPN) reported collaboration revenue (ZURZUVAE) — total revenues of $27.64M in Q1 2026.
What does collaboration revenue (ZURZUVAE) — total revenues mean?: This metric represents the total revenue recognized from collaborative arrangements or licensing agreements associated with a specific pharmaceutical product or therapeutic candidate. It reflects the financial inflows generated through partnerships, milestone payments, or profit-sharing models rather than direct product sales. Monitoring this revenue stream provides insight into the company's ability to monetize its research and development pipeline through strategic external alliances.